Ideas
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
5:53
Battery bottom; start small, add later.
He views the Korean battery sector as being in the final tunnel: 2026 estimates are being cut and may show negative growth, but the bad news is largely priced in and smart money is starting to test the bottom. Catalysts include new orders, Europe/China FSD approval in February, InterBattery in March, and Tesla Cybercab production in April; he would only start with a small position now and add in February.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
8:32
Semiconductors lead first-half market.
He says semiconductors should remain the leading KOSPI sector in the first half, driven by hardware earnings surprises at Samsung Electronics and SK hynix and continued AI demand. He treats semiconductors as the main market engine despite macro noise.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
10:58
Cosmetics exports diversify; buy APR, Silicon2.
He argues Korean cosmetics exporters are moving from a qualitative win in 2025 to a quantitative win in 2026 as export data show volume growth and diversification beyond the US into the Middle East and Asia despite tariffs. NH's official top picks are APR and Silicon2, while large-cap Amorepacific is favored but investors should enter after a weak Q4 on final cost charges.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
12:26
Front-end equipment valuations look stretched.
He warns front-end semiconductor equipment names TES and Wonik IPS have exceeded historical valuation bands and are pricing in Samsung foundry capex and order announcements that have not been officially confirmed. If Samsung Electronics falls 3%, these can fall about 10%, so investors should be cautious and take profits.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
13:11
Rotate to materials and back-end equipment.
Within Korean semiconductor small and mid-caps, he prefers relatively less-risen materials stocks and a rotation from front-end equipment toward back-end equipment such as EO Technics, citing overnight strength in ASM Holdings as a sign of where equipment interest is shifting.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
19:14
Oil supply overhang pressures prices.
He expects crude oil to trend lower over the medium to long term because Venezuela-related supply and eventual production normalization point to oversupply, which should also ease inflation pressure. He frames the energy and oil view as neutral-to-downward rather than a spike risk.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
24:14
US equities remain strong in 2026.
He says there is consensus that the US market remains strong in 2026 even as macro worries persist. The US is still the resilient equity market, though he also sees a later rotation back toward US assets after first-half non-US strength.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
24:38
KOSPI re-rates toward 5,550.
NH's official KOSPI band has an upper target of 5,550 and a lower bound around 4,000, with the upper end possibly touched in the second quarter. He argues Korea is moving from a chronic discount to a premium and that it is not time to sell Korean stocks.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
25:41
USD/KRW stays elevated then rises.
He expects USD/KRW to trade in the 1,400-1,450 range in the first half, then sees renewed won weakness afterward as the dollar trend changes.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
28:34
Samsung Electronics has more upside than hynix.
He prefers Samsung Electronics over SK hynix for more upside, with NH's official target at KRW 155,000 and potential to raise it after Q1 results and Q2 guidance. He cites foundry and NAND exposure as areas where Korea could benefit, while warning that expectations are high and a short-term pullback is possible.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
29:25
Korean biotech is a top H1 sector.
He calls Korean biotech and pharma one of the most promising H1 sectors and a plus-alpha area after a dark bottom phase, helped by Celltrion's earnings surprise, new drug pipelines, CDMO strength, and obesity momentum.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
29:25
Celltrion bottomed; 50% upside.
Celltrion showed a strong Q4 operating-profit surprise around KRW 467bn versus consensus, signaling the biotech bottom. He sees 2026 brighter on Zymfentra ramp, US plant sales, biosimilar core business, and ADC momentum; buy on dips or hold for more than 50% upside.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
30:07
Samsung Biologics still a core CDMO hold.
He does not view Samsung Biologics as a stock to abandon; it remains a large-cap CDMO holding, but new plant utilization is the key and market expectations are high after the spin-off, so it carries more weight and less upside versus Celltrion.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
30:50
KEPCO benefits from nuclear and power rates.
He is positive on KEPCO as it rallies with the nuclear and SMR theme and sees a chance that electricity rates rise in 2026 despite a softer Q1, with nuclear power as the most important driver.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
31:00
Doosan Enerbility leads Korean SMR theme.
Doosan Enerbility is rising strongly with US SMR and nuclear stocks and plays the role of the Korean nuclear and SMR leader, keeping the theme attractive.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
31:33
Holding-company proxies benefit from chip rally.
As Samsung Electronics and SK hynix rally, he points to their holding-company proxies Samsung C&T and SK Square as related stocks to consider.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
31:44
Hyundai is a physical-AI robotics play.
He wants Hyundai Motor viewed through physical AI and robotics rather than only EVs. US hybrid sales are rising, and 2026 KPIs plus a possible Boston Dynamics IPO are catalysts. He favors watching Hyundai Motor and Hyundai Mobis.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
33:35
Kia's Mexico exposure is a risk.
He says Kia is ambiguous because its plants are heavily set up in Mexico, leaving it exposed if the US pressures Mexico on trade.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
36:56
Hold SpaceX suppliers with real orders.
He says real SpaceX value-chain companies with actual order references should continue to be held, even though short-term space-theme profit-taking is likely.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
37:18
Intellian growth should lift shares.
He cites satellite-related Intellian Technologies as a name with triple-digit growth, arguing that such performance should eventually be reflected in the stock price.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
38:43
Samsung Electro-Mechanics is underpriced AI supplier.
He argues Samsung Electro-Mechanics is misvalued as a traditional substrate maker at 15-20x earnings when it should earn a 30-40x multiple as a physical AI core component supplier. Its camera modules, MLCCs, and package substrates can benefit from Tesla and robot actuator demand; its market cap is only about KRW 20tn versus LG Energy Solution's KRW 90tn while operating profit is catching up.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
46:17
Obesity drug theme remains a must-own.
He says obesity is a sector investors must keep for 2026, not abandon. In the US, Eli Lilly is the top pick; in Korea he favors Hanmi Pharm and D&D Pharmatech, and also points to ABL Bio and HanAll Biopharma as oral and obesity-related names.
Park Ji-hoon
Director, Asset Management Consulting Dept., NH Investment & Securities
48:54
EcoPro BM benefits from lithium rebound.
EcoPro BM's earnings can inflect as rising lithium carbonate prices lift inventory valuation. The 120-day moving average provides important downside support, so the risk/reward is improving, though rallies should be sold into.
This 3PRO TV (삼프로TV) video, published January 05, 2026,
features Park Ji-hoon
discussing 006400.KS, 373220.KS, 003670.KS, L&F, SMH, APR, 257720.KQ, 090430.KS, 095610.KQ, WONIK IPS, Semiconductor materials sector, 030200.KS, WTI, SPY, EWY, USD/KRW, 005930.KS, Korean biotech/pharma, 068270.KS, 207940.KS, 015760.KS, 034020.KS, 028260.KS, 402340.KS, 005380.KS, 012330.KS, 000270.KS, SPCX, 189300.KQ, 009150.KS, LLY, 128940.KS, 347850.KQ, ABL Bio, 009420.KS, 247540.KQ.
23 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Park Ji-hoon
· Tickers:
006400.KS,
373220.KS,
003670.KS,
L&F,
SMH,
APR,
257720.KQ,
090430.KS,
095610.KQ,
WONIK IPS,
Semiconductor materials sector,
030200.KS,
WTI,
SPY,
EWY,
USD/KRW,
005930.KS,
Korean biotech/pharma,
068270.KS,
207940.KS,
015760.KS,
034020.KS,
028260.KS,
402340.KS,
005380.KS,
012330.KS,
000270.KS,
SPCX,
189300.KQ,
009150.KS,
LLY,
128940.KS,
347850.KQ,
ABL Bio,
009420.KS,
247540.KQ
